FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115927424> ?p ?o ?g. }

• W3115927424 endingPage "1062" @default.
• W3115927424 startingPage "1056" @default.
• W3115927424 abstract "OBJECTIVE To explore the effectiveness and safety of golimumab in the treatment of severe/refractory cardiovascular Behcet syndrome (BS). METHODS We retrospectively analyzed the clinical data of nine patients diagnosed with severe/refractory cardiovascular BS and treated with golimumab from February 2018 to July 2020 in Peking Union Medical College Hospital. We analyzed levels of erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP), imaging findings, and the doses of glucocorticoids and immunosuppressive agents during the period of combined treatment with golimumab. RESULTS Nine patients were enrolled, including 8 males and 1 female, with a mean age and median course of (37.0±8.6) years and 120 (60, 132) months, respectively. Seven patients presented with severe aortic regurgitation combined with other cardiovascular involvement secondary to BS. Two patients presented with large vessel involvement, including multiple aneurysms and vein thrombosis. Prior to golimumab treatment, seven patients were treated with glucocorticoids and multiple immunosuppres-sants [with a median number of 3 (1, 3) types] while still experienced disease progression or elevated inflammation biomarkers during postoperative period. Eight patients with disease progression, uncontrolled inflammation and history of severe postoperative complications required effective and fast control of inflammation during perioperative period. One patient had adverse reaction with tocilizumab and switched to golimumab during perioperative period. The patients were treated with golimumab 50 mg every 4 weeks, along with concomitant treatment of glucocorticoid and immunosuppressants. After a median follow-up of (16.3±5.6) months, all the patients achieved clinical improvement. Vascular lesions were radiologically stable and no vascular progressive or newly-onset of vascular lesions was observed. The eight patients who experienced cardiac or vascular operations showed no evidence of postoperative complications. The ESR and hsCRP levels decreased significantly [16.5 (6.8, 52.5) mm/h vs. 4 (2, 7) mm/h, and 21.24 (0.93, 32.51) mg/L vs. 0.58 (0.37, 1.79) mg/L (P < 0.05), respectively]. The dose of prednisone was tapered from 35 (15, 60) mg/d to 10.0 (10.0, 12.5) mg/d. No prominent adverse reactions were observed. CONCLUSION Our study suggests that golimumab is effective in the treatment of severe/refractory cardiovascular BS. Combination immunosuppression therapy with golimumab contributes to control of inflammation, reduction of postoperative complications and tapering the dose of glucocorticoids or immunosuppressants." @default.
• W3115927424 created "2021-01-05" @default.
• W3115927424 creator A5008382096 @default.
• W3115927424 creator A5034971496 @default.
• W3115927424 creator A5042923703 @default.
• W3115927424 creator A5045844525 @default.
• W3115927424 creator A5047828152 @default.
• W3115927424 creator A5073523669 @default.
• W3115927424 creator A5083622692 @default.
• W3115927424 creator A5088041830 @default.
• W3115927424 date "2020-12-18" @default.
• W3115927424 modified "2023-10-01" @default.
• W3115927424 title "[Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome]" @default.
• W3115927424 cites W1176283365 @default.
• W3115927424 cites W1455231073 @default.
• W3115927424 cites W1972240373 @default.
• W3115927424 cites W1981448840 @default.
• W3115927424 cites W1983498156 @default.
• W3115927424 cites W1999144072 @default.
• W3115927424 cites W2007143253 @default.
• W3115927424 cites W2009923660 @default.
• W3115927424 cites W2022237635 @default.
• W3115927424 cites W2023597481 @default.
• W3115927424 cites W2045850959 @default.
• W3115927424 cites W2050142754 @default.
• W3115927424 cites W2076668534 @default.
• W3115927424 cites W2089588732 @default.
• W3115927424 cites W2096380177 @default.
• W3115927424 cites W2120630259 @default.
• W3115927424 cites W2120852203 @default.
• W3115927424 cites W2125412499 @default.
• W3115927424 cites W2140965629 @default.
• W3115927424 cites W2158058290 @default.
• W3115927424 cites W2158131108 @default.
• W3115927424 cites W2229948257 @default.
• W3115927424 cites W2275572529 @default.
• W3115927424 cites W2330769075 @default.
• W3115927424 cites W2333086950 @default.
• W3115927424 cites W2404327936 @default.
• W3115927424 cites W2471841098 @default.
• W3115927424 cites W2559955759 @default.
• W3115927424 cites W2560437439 @default.
• W3115927424 cites W2604128221 @default.
• W3115927424 cites W2605907355 @default.
• W3115927424 cites W2763598680 @default.
• W3115927424 cites W2765359299 @default.
• W3115927424 cites W2795891386 @default.
• W3115927424 cites W2887666249 @default.
• W3115927424 cites W29053593 @default.
• W3115927424 cites W2924518578 @default.
• W3115927424 cites W2926902750 @default.
• W3115927424 cites W3001875277 @default.
• W3115927424 cites W3019938127 @default.
• W3115927424 cites W3044915338 @default.
• W3115927424 cites W640317310 @default.
• W3115927424 cites W2027832454 @default.
• W3115927424 doi "https://doi.org/10.19723/j.issn.1671-167x.2020.06.011" @default.
• W3115927424 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7745271" @default.
• W3115927424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33331313" @default.
• W3115927424 hasPublicationYear "2020" @default.
• W3115927424 type Work @default.
• W3115927424 sameAs 3115927424 @default.
• W3115927424 citedByCount "1" @default.
• W3115927424 countsByYear W31159274242022 @default.
• W3115927424 crossrefType "journal-article" @default.
• W3115927424 hasAuthorship W3115927424A5008382096 @default.
• W3115927424 hasAuthorship W3115927424A5034971496 @default.
• W3115927424 hasAuthorship W3115927424A5042923703 @default.
• W3115927424 hasAuthorship W3115927424A5045844525 @default.
• W3115927424 hasAuthorship W3115927424A5047828152 @default.
• W3115927424 hasAuthorship W3115927424A5073523669 @default.
• W3115927424 hasAuthorship W3115927424A5083622692 @default.
• W3115927424 hasAuthorship W3115927424A5088041830 @default.
• W3115927424 hasConcept C121332964 @default.
• W3115927424 hasConcept C126322002 @default.
• W3115927424 hasConcept C141071460 @default.
• W3115927424 hasConcept C142424586 @default.
• W3115927424 hasConcept C2779134260 @default.
• W3115927424 hasConcept C2780132546 @default.
• W3115927424 hasConcept C2781290027 @default.
• W3115927424 hasConcept C31174226 @default.
• W3115927424 hasConcept C71924100 @default.
• W3115927424 hasConcept C87355193 @default.
• W3115927424 hasConcept C90924648 @default.
• W3115927424 hasConceptScore W3115927424C121332964 @default.
• W3115927424 hasConceptScore W3115927424C126322002 @default.
• W3115927424 hasConceptScore W3115927424C141071460 @default.
• W3115927424 hasConceptScore W3115927424C142424586 @default.
• W3115927424 hasConceptScore W3115927424C2779134260 @default.
• W3115927424 hasConceptScore W3115927424C2780132546 @default.
• W3115927424 hasConceptScore W3115927424C2781290027 @default.
• W3115927424 hasConceptScore W3115927424C31174226 @default.
• W3115927424 hasConceptScore W3115927424C71924100 @default.
• W3115927424 hasConceptScore W3115927424C87355193 @default.
• W3115927424 hasConceptScore W3115927424C90924648 @default.
• W3115927424 hasIssue "6" @default.
• W3115927424 hasLocation W31159274241 @default.
• W3115927424 hasOpenAccess W3115927424 @default.

• next